Business ❯ Finance ❯ Mergers and Acquisitions

Pharmaceuticals

Obesity Drugs Oncology Alkermes and Avadel Pharmaceuticals Eli Lilly Torrent Pharmaceuticals Biotech Companies 23andMe Biotechnology Novo Holdings Acquisition Rare Diseases

Eli Lilly to Acquire Centessa for $6.3 Billion With Potential Payout Up to $7.8 Billion

The purchase gives Lilly a foothold in orexin-based sleep medicine with a shot at a multibillion-dollar market.

Biogen to Buy Apellis for $5.6 Billion in Cash, Adding Syfovre and Empaveli

Merck to Acquire Terns for $6.7 Billion to Add Promising Leukemia Drug

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

Gilead to Acquire Arcellx for Up to $7.8 Billion to Gain Full Control of CAR-T Anito-Cel

USV to Acquire 79% of Wellbeing Nutrition in Rs 1,583 Crore All-Cash Deal

Merck Ends Revolution Medicines Takeover Talks After Valuation Standoff

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

Lundbeck Challenges Alkermes With Up to $23-Per-Share Offer for Avadel

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

Pfizer Clinches $10 Billion Metsera Deal After Novo Nordisk Withdraws

Metsera Backs Pfizer’s $10 Billion Deal, Citing Regulatory Risks in Novo Bid

Pfizer Sues to Block Novo Nordisk’s Higher Metsera Bid as Board Backs Revised Offer

Pfizer Wins Early U.S. Antitrust Clearance for Metsera Deal as Novo’s Higher Bid Pressures Timeline

Lilly to Buy Adverum in Gene‑Therapy Deal Worth Up to $12.47 a Share

Alkermes to Buy Avadel in Up to $2.1 Billion Deal With CVR Tied to Lumryz Expansion

CCI Clears Torrent–JB Chemicals Deal With Voluntary Remedies

Lupin’s Nanomi to Acquire VISUfarma for €190 Million to Expand European Eye‑Care Portfolio

Pfizer to Buy Metsera for $4.9 Billion Upfront in Return to Obesity Drugs

Novartis to Acquire Tourmaline Bio for $1.4 Billion to Bolster Heart-Drug Pipeline